Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Chief Business Officer | September 24, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,056 |
Reported balance
After 2026-09-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-24 · Gift · Disposed 17,100 · Balance 14,056 F1: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Common StockSEC Table I · non-derivative | IndirectCustodial Account for Child | 20,571 |
Reported balance
After 2026-09-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-24 · Gift · Acquired 5,000 · Balance 20,571 F2: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. |
| Common StockSEC Table I · non-derivative | IndirectCustodial Account for Child | 20,571 |
Reported balance
After 2026-09-24 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-24 · Gift · Acquired 5,000 · Balance 20,571 F3: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. |
| Common StockSEC Table I · non-derivative | IndirectGary Charles Robb TTE Robb Revocable Trust | 39,716 |
Reported balance
Holding disclosure · report date 2026-09-24 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 39,716 F4: These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
F3: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
F4: These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-405402 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 20,571 F3 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| September 24, 2026 Filed Sep 28, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-405402 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 20,571 F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| September 24, 2026 Filed Sep 28, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 17,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-405402 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,056 F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 23:47 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 17,493 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0001193125-26-395827 · ownership.xml · derivative · entry 5 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,507 Underlying: Common Stock · 17,493 shares Expires 2027-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 23:47 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 17,493 | $8.27 | $144,667.11 |
DisclosureSEC source: 0001193125-26-395827 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 01:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 91 | $113.38 | $10,317.58 |
DisclosureSEC source: 0001193125-26-382457 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,663 F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F6 · price: The closing price on September 1, 2026 was used to calculate the withholding obligation. F7 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 164 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-382457 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,754 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 164 | $113.38 | $18,594.32 |
DisclosureSEC source: 0001193125-26-382457 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,590 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 10,000 | $116.26 | $1,162,572.00 |
DisclosureSEC source: 0001193125-26-355560 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Gary Charles Robb TTE Robb Revocable Trust Disclosed balance after: 39,716 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.00 to $116.54 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F3 · ownership.nature: These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 125 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355560 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,426 F1 · balance_after: Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:31 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-352428 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 15,571 F3 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:31 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-352428 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 15,571 F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:31 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 11,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-352428 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,551 F1 · balance_after: Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 23:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 358 | $70.44 | $25,217.52 |
DisclosureSEC source: 0001193125-26-256002 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,681 F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F6 · price: The closing price on June 1, 2026 was used to calculate the withholding obligation. F7 · balance_after: Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, and 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 776 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-256002 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,039 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, and 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 776 | $70.44 | $54,661.44 |
DisclosureSEC source: 0001193125-26-256002 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,263 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, and 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 27, 2026 Filed Jul 9, 2026 00:01 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-298871 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,081 F1 · balance_after: Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 13, 2026 Filed May 15, 2026 22:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-227411 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 12,571 F3 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| May 13, 2026 Filed May 15, 2026 22:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-227411 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 12,571 F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| May 13, 2026 Filed May 15, 2026 22:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 5,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-227411 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,487 F1 · balance_after: Includes 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, and 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Excludes 49,716 shares previously owned directly which were transferred to the Gary Charles Robb TTE Robb Revocable Trust. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 01:21 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 121 | $35.97 | $4,352.37 |
DisclosureSEC source: 0001193125-26-092158 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,503 F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F6 · price: The closing price on March 2, 2026 was used to calculate the withholding obligation. F7 · balance_after: Includes 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, and 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 224 share underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:21 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 499 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092158 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,624 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 224 share underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:21 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 499 | $35.97 | $17,949.03 |
DisclosureSEC source: 0001193125-26-092158 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,125 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 224 share underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:13 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $35.70 | $0.00 |
DisclosureSEC source: 0001193125-26-089010 · ownership.xml · derivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 145,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001193125-25-335575 · ownership.xml · derivative · entry 5 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,000 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 80,284 | $83.59 | $6,710,939.56 |
DisclosureSEC source: 0001193125-25-335575 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,626 F2 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability from a net (cashless) exercise of options. F1 · balance_after: Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, and 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 145,000 | $3.88 | $562,600.00 |
DisclosureSEC source: 0001193125-25-335575 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, and 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:22 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 148 | $79.78 | $11,807.44 |
DisclosureSEC source: 0001193125-25-307213 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,910 F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F6 · price: The closing price on December 1, 2025 was used to calculate the withholding obligation. F3 · balance_after: Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:22 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 224 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-307213 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,058 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:22 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 224 | $79.78 | $17,870.72 |
DisclosureSEC source: 0001193125-25-307213 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,834 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 23:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 256 | $71.38 | $18,273.28 |
DisclosureSEC source: 0001193125-25-196309 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,610 F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F6 · price: The closing price on September 2, 2025 was used to calculate the withholding obligation. F3 · balance_after: Includes 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 251 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-196309 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,866 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 251 | $71.38 | $17,916.38 |
DisclosureSEC source: 0001193125-25-196309 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,615 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 2, 2025. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 22:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001193125-25-188869 · ownership.xml · derivative · entry 6 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 5,000 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 22:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 2,674 | $71.17 | $190,308.58 |
DisclosureSEC source: 0001193125-25-188869 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,364 F2 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability from a net (cashless) exercise of options. F1 · balance_after: Includes 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 22:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,326 | $71.27 | $165,774.02 |
DisclosureSEC source: 0001193125-25-188869 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,038 F1 · balance_after: Includes 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 22:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,000 | $3.88 | $19,400.00 |
DisclosureSEC source: 0001193125-25-188869 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 22:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,185 | $70.77 | $225,402.45 |
DisclosureSEC source: 0000950170-25-088005 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,364 F1 · balance_after: Includes 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 00:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 651 | $71.68 | $46,663.68 |
DisclosureSEC source: 0000950170-25-081932 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,549 F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F6 · price: The closing price on June 2, 2025 was used to calculate the withholding obligation. F3 · balance_after: Includes 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 997 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-081932 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,200 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 997 | $71.68 | $71,464.96 |
DisclosureSEC source: 0000950170-25-081932 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,203 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 360 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-076417 · ownership.xml · nonDerivative · entry 4 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 11,571 F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 360 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-076417 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 11,571 F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-076417 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,206 F1 · balance_after: Includes 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,279 | $75.85 | $172,862.15 |
DisclosureSEC source: 0000950170-25-076417 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,586 F1 · balance_after: Includes 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 20, 2025 Filed Mar 25, 2025 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 233 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-044069 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 10,898 F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| March 20, 2025 Filed Mar 25, 2025 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 233 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-044069 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 10,898 F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039604 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 10,665 F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039604 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 10,665 F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 4,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039604 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,865 F1 · balance_after: Includes 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.